U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Matthew Brennan - 03/17/2017
  1. Warning Letters

CLOSEOUT LETTER

Matthew Brennan

Recipient:
Matthew Brennan

United States

Issuing Office:

United States

 

  

Black HHS-Blue FDA Logo

 

 

 
New York District
158-15 Liberty Ave
Jamaica, NY 11433 

March 17, 2017

Matthew E. Brennan
2089 Doolittle Road
Sauquoit, New York 13456-2409

Dear Mr. Brennan:

The Food and Drug Administration has completed an evaluation of your corrective actions in response to our Warning Letter NYK-2016-27, dated March 3, 2016. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

CDR Frank Verni, RpH
Compliance Officer
U.S. Food & Drug Administration
New York District Office 

Back to Top